Péntek Márta, Kobelt Gisela, Berg Jenny, Capsa Daniela, Dalén Johan, Bíró Zita, Mátyás Klotild, Komoly Sámuel
Corvinus University of Budapest, Budapest, Hungary.
European Health Economics, Mulhouse, France.
Mult Scler. 2017 Aug;23(2_suppl):91-103. doi: 10.1177/1352458517708142.
To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated.
This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of disability, from the societal perspective, in HUF 2015.
A total of 521 patients (mean age 47 years) participated; 85% were below retirement age, and of these, 47% were employed. Employment was related to disability and MS affected productivity at work for 82% of those working. Overall, 94% and 66% of patients experienced fatigue and cognitive difficulties as a problem, respectively. The mean utility and annual costs were 0.691 and 3,432,000HUF at Expanded Disability Status Scale (EDSS) 0-3, 0.491 and 5,262,000HUF at EDSS 4-6.5 and 0.076 and 6,235,000HUF at EDSS 7-9, respectively. The average cost of a relapse was estimated at 240,500HUF.
This study illustrates the burden of MS on Hungarian patients and provides current data that are important for the development of health policies.
为了评估针对多发性硬化症（MS）的干预措施的价值——在无法观察到终身成本和结果的情况下——结果数据必须与成本相结合。这就要求定期更新成本数据。
本研究是一项在16个国家开展的横断面回顾性研究的一部分，收集了MS患者的资源消耗、工作能力、健康相关生活质量（HRQoL）和常见症状的数据。从社会角度，以2015匈牙利福林为单位，按残疾程度进行描述性分析。
共有521名患者（平均年龄47岁）参与；85%未到退休年龄，其中47%有工作。就业与残疾有关，82%的在职患者的工作效率受到MS影响。总体而言，分别有94%和66%的患者将疲劳和认知困难视为问题。在扩展残疾状态量表（EDSS）0 - 3级时，平均效用和年度成本分别为0.691和3,432,000匈牙利福林；在EDSS 4 - 6.5级时，为0.491和5,262,000匈牙利福林；在EDSS 7 - 9级时，为0.076和6,235,000匈牙利福林。一次复发的平均成本估计为240,500匈牙利福林。
本研究说明了MS给匈牙利患者带来的负担，并提供了对卫生政策制定很重要的当前数据。
